132 related articles for article (PubMed ID: 38760161)
21. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma.
AlShareef S; McDonald CF; Lee J
J Asthma Allergy; 2022; 15():209-217. PubMed ID: 35210787
[TBL] [Abstract][Full Text] [Related]
23. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
24. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
[TBL] [Abstract][Full Text] [Related]
25. Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L; Wang Z; Cui L; Xu Y; Guan K; Zhao B
Clin Transl Allergy; 2021 Jun; 11(4):e12038. PubMed ID: 34123366
[TBL] [Abstract][Full Text] [Related]
26. [The Effectiveness of Mepolizumab and Benralizumab in a Real-Life Cohort of Patients with Severe Eosinophilic Asthma].
Espinosa de Los Monteros Garde MJ; Romero Sanz V; Blázquez Romero C
Open Respir Arch; 2021; 3(2):100103. PubMed ID: 37497072
[TBL] [Abstract][Full Text] [Related]
27. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
29. Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study.
Blaiss M; Bleecker ER; Jacob-Nara J; Nair R; Duh MS; Wang Z; Stanford RH; Soler X; Hardin M; Ye M; Khanal A; Borsos K
Ann Allergy Asthma Immunol; 2024 Apr; 132(4):463-468.e1. PubMed ID: 37967668
[TBL] [Abstract][Full Text] [Related]
30. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
31. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
32. Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Jingo K; Harada N; Nishioki T; Torasawa M; Yamada T; Asao T; Takagi H; Takeshige T; Ito J; Takahashi K
Allergy Asthma Clin Immunol; 2020; 16():46. PubMed ID: 32536947
[TBL] [Abstract][Full Text] [Related]
33. Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma.
Bateman ED; Khan AH; Xu Y; Guyot P; Chao J; Kamat S; Rowe P; Burnett H; Msihid J; Weinreich D; Pavord ID
Respir Med; 2022 Jan; 191():105991. PubMed ID: 35090688
[TBL] [Abstract][Full Text] [Related]
34. Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts.
Kimura Y; Suzukawa M; Inoue N; Imai S; Horiguchi H; Akazawa M; Matsui H
Asian Pac J Allergy Immunol; 2024 Jan; ():. PubMed ID: 38183647
[TBL] [Abstract][Full Text] [Related]
35. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
[TBL] [Abstract][Full Text] [Related]
36. Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2.
Carstens D; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Chung Y
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2150-2161.e4. PubMed ID: 37146880
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
38. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
39. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
[TBL] [Abstract][Full Text] [Related]
40. Characterization of Severe Uncontrolled Asthma in Japan: Analysis of Baseline Data from the PROSPECT Study.
Koya T; Asai K; Iwanaga T; Hara Y; Takahashi M; Makita N; Hayashi N; Tashiro N; Tohda Y
J Asthma Allergy; 2023; 16():597-609. PubMed ID: 37288424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]